Design and synthesis of 13,14-dihydro prostaglandin F(1α) analogues as potent and selective ligands for the human FP receptor

Journal of Medicinal Chemistry

Volumn 43, Issue 5, 2000, Pages 945-952

  Wang, Yili ^a   Wos, John A ^a   Dirr, Michelle J ^a   Soper, David L ^a   DeLong, Mitchell A ^a   Mieling, Glen E ^a   De, Biswanath ^a   Amburgey, Jack S ^a   Suchanek, Eric G ^a   Taylor, Cynthia J ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F1 ALPHA; PROSTAGLANDIN RECEPTOR;

ANIMAL CELL; ARTICLE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; OSTEOPOROSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING, COMPETITIVE; COS CELLS; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; OSTEOPOROSIS; PROSTAGLANDINS F; RADIOLIGAND ASSAY; RATS; RECEPTORS, PROSTAGLANDIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034624699     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990542v     Document Type: Article

References (40)

1. (a) Ueda, K.; Saito, S.; Najano, H.; Aoshima, M.; Yokata, M.; Muraoka, R.; Iwaya, T. Cortical hyperostosis following long-term administration of prostaglandin E-1 in infants with cyanotic congential heart disease. J. Pediatr. 1980, 97, 834-836.
2. 2 in rapidly growing rats: Depressed longitudinal and radial growth and increased metaphyseal hard tissue mass. Bone 1985, 6, 79-86.
3. 2α on the Skeleton of Osteopenic Ovariectomized Rats. Bone 1995, 17, 549-554.
4. Jee, W. S. S.; Ma, Y. F. The In Vivo Anabolic Actions of Prostaglandins in Bone. Bone 1997, 21, 297-304.
5. 2 Increases Bone Strength in Intact Rats and Ovariectomized Rats with Established Osteoporosis. Bone 1998, 23, 249-255.
6. (a) Coleman, R. A.; Humphrey, P. P. A.; Kennedy, I.; Lumley, P. Prostanoid receptors - the development of a working classification. Trends Pharmacol. Sci. 1984, 303-306.
7. (b) Coleman, R. A.; Humphrey, P. P. A.; Kennedy, I. Prostanoid Receptors in Smooth muscle: Further evidence for a proposed classification. Trends Autonom. Pharmacol. 1982, 3, 35.
8. Kiriyama, M.; Ushikui, F.; Kobayashi, T.; Hirata, M.; Sugimoto, Y.; Narumiya, S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 1997, 122, 217-224.
9. Jackson, P. S.; Jessup, R. Secondary pharmacological properties of prostaglandins. Vet. Rec. 1984, 114, 168.
10. (a) Negishi, M.; Sugimoto, Y.; Ichikawa, A. Molecular mechanism of diverse actions of prostanoid receptors. Biochim. Biophys. Acta 1995, 1259, 109-120.
11. (b) Abramovitz, M.; Metters, K. M. Prostanoid Receptors. Annu. Rep. Med Chem. 1998, 33, 223-232.
12. Bartman, W.; Beck, G.; Lerch, U.; Teufel, W.; Scholkens, B. Luteolytic Prostaglandins. Synthesis and Biological Activity. Prostaglandins 1979, 17, 301-311.
13. 2α analogues for luteolysis in cattle. J. Vet. Pharmacol. Ther. 1979, 2, 223-229.
14. (a) Stjernschantz, J.; Resul, B. Phenyl substituted prostaglandin analogues for glaucoma treatment. Drugs Future 1992, 17, 691-704.
15. (b) Resul, B.; Stjernschantz, J.; No, K.; Liljebris, C.; Selen, G.; Astin, M.; Karlsson, M.; Bito, L. Z. Phenyl-Substituted Prostaglandins: Potent and Selective Antiglaucoma Agents. J. Med. Chem. 1993, 36, 243-248.
16. 2α Isopropyl Ester: Potential Antiglaucoma Agents. J. Med. Chem. 1995, 38, 289-304.
17. Liljebris, C.; Nilsson, B.; Resul, B.; Hacksell. U. J. Org. Chem. 1996, 61, 4028-4034.
18. Commercially available from Cayman Chemical, Ann Arbor, MI 48108.
19. Corey, E. J.; Cho, H.; Rucker, C.; Hua, D. Studies with Trialkylsilyltriflates: New Syntheses and Applications. Tetrahedron Lett. 1981, 22, 3455-3548.
20. (a) House, H. O.; Chu, C. Y.; Wilkins, J. M.; Umen, M. J. The Chemistry of Carbanions. XXVII. A Convenient Precursor for the Generation of Lithium Organocuprates. J. Org. Chem. 1975, 40, 1460.
21. (b) Bertz, S. H.; Gibson, C. P.; Dabbagh, G. The Preparation of Lithium Organocuprates From Various Cu(I) Salts. Tetrahedron Lett. 1987, 28, 4251-4254.
22. Erdik, E. Copper (I) Catalyzed Reactions of Organolithiums and Grignard Reagents. Tetrahedron 1984, 40, 641-657.
23. For a review see: Smith, J. G. Synthetically Useful Reactions of Epoxides. Synthesis 1984, 629-656 and references therein.
24. 2O in methanol) chromatography.
25. (a) Abramovitz, M.; Boie, Y.; Nguyen, T.; Rushmore, T. H.; Bayne, M. A.; Metters, K. M.; Slipetz, D. M.; Grygorczyk, R. Cloning and Expression of a cDNA for the Human Prostanoid FP Receptor. J. Biol. Chem. 1994, 269, 2632-2636.
26. (b) Pierce, K. L.; Bailey, T. J.; Hoyer, P. B.; Gil. D. W.; Woodward, D. F.; Regan, J. W. Cloning of a Carboxyl-terminal Isoform of the Prostanoid FP Receptor. J. Biol. Chem. 1997, 272, 883-887 and references therein.
27. 2 Receptor Allows Discrimination between Agonist and Antagonist Binding Sites. Mol. Pharmacol. 1993, 44, 934-939.
28. (b) Cascierci, M. A.; Fong, T. M.; Strader, C. D. Identification of critical functional groups within binding pockets of G-protein-coupled receptors. Drugs Future 1996, 21, 521-527.
29. (a) Peitsch, M. C.; Herzyk, P.; Wells, T. N. C.; Hubbard, R. E. Automated Modeling of the Transmembrane Region of G-coupled Protein Receptor by Swiss-model. Receptors Channels 1996, 4, 161-164.
30. (b) Using TRIPOS computational tools (Sybyl 6.6), several variants of the hFP receptor model were created with the mapping procedure described in the text. Several orientations of various receptor helices were investigated, and different conformations of known FP agonists were docked into the putative models and evaluated. The homology model presented in this paper best explains the SAR data discussed.
31. 3 = 744 nM) than the meta-substituted analogues, suggesting that a finite space exists at the bottom of the receptor.
32. (a) Hartke, J. R.; Lundy, M. W.; deLong, M. A. Method of Increasing Bone Volume Using Non-Naturally Occurring FP Agonists. WO 9912550, 1999; Chem. Abstr. 1999, 194004.
33. (a) Hartke, J. R.; Lundy, M. W.; deLong, M. A. Method of Increasing Bone Volume Using Non-Naturally Occurring FP Agonists. WO 9912550, 1999; Chem. Abstr. 1999, 194004.
34. 20-Substituted Tetrahydro Prostaglandins Useful as FP Agonists. WO 9912895, 1999; Chem. Abstr. 1999, 194115.
35. 20-Substituted Tetrahydro Prostaglandins Useful as FP Agonists. WO 9912895, 1999; Chem. Abstr. 1999, 194115.
36. 1α Analogues. WO 9912897, 1999; Chem. Abstr. 1999, 194117. For a preliminary account of the in vivo effects of these compounds, see:
37. 1α Analogues. WO 9912897, 1999; Chem. Abstr. 1999, 194117. For a preliminary account of the in vivo effects of these compounds, see:
38. Hartke, J. R.; Jankowsky, M. L.; deLong, M. A.; Soehner, M. E.; Jee, W. S. S.; Lundy, M. W. Prostanoid FP Agonists Build Bone in the Ovariectomized Rat. J. Bone Miner. Res. 1999, 14, Suppl. 1, S207.
39. (e) deLong, M. A.; Hartke, J. R.; Jankowsky, M. L.; Soehner, M. E.; Wos, J. A.; Soper, D. L. Lundy, M. W. Tetrahydro-fluprostenol, a 17-Phenyl Saturated Prostanoid FP Receptor Agonist, is a Bone Anabolic Agent in the Aged, OVX Rat. J. Bone Miner. Res. 1999, 14, Suppl. 1, S275. A complete evaluation of the in vivo effects of this class of compounds will be reported in due course.
40. 1 Series. Prostaglandins 1975, 9, 1-4.